MASLD in Type 2 Diabetes in Primary Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

317 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-16

Study Completion Date

2034-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis Advanced Fibrosis Sarcopenia Obesity & Overweight Type 2 Diabetes Hypertension OSAS (Obstructive Sleep Apneas Syndrome) Metabolic Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

MASLD Fibroscan PDFF MRE Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously included and fulfilled evaluation in EPSONIP trial (NCT03864510)
* Age \>/= 18 years
* Informed consent

Exclusion Criteria

* Contraindication to magnetic resonance
* Other primary liver disease than MASLD diagnosed after inclusion EPSONIP trial (NCT03864510)
* Liver transplantation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Patrik Nasr

Adj Associate Professor, Docent, Specialist doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrik Nasr, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Department of Health, Medicine and Caring Sciences, Linköping University, and Department of Gastroenterology and Hepatology, Linköping University Hospital, Linköping, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Gastroenterology and Hepatology, Linköping University Hospital

Linköping, Östergötland County, Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-05471-01

Identifier Type: -

Identifier Source: org_study_id

MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study